MCID: GNT002
MIFTS: 57

Giant Cell Glioblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Giant Cell Glioblastoma

MalaCards integrated aliases for Giant Cell Glioblastoma:

Name: Giant Cell Glioblastoma 11 58 53 5 14 71
Monstrocellular Sarcoma 11 71
Giant-Cell Glioblastoma 75

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:3074
MeSH 43 D005909
NCIt 49 C4325
SNOMED-CT 68 44529004
ICD10 via Orphanet 32 C71.9
UMLS via Orphanet 72 C0334588
Orphanet 58 ORPHA251579
UMLS 71 C0334588 C0334593

Summaries for Giant Cell Glioblastoma

Disease Ontology: 11 A glioblastoma that is characterized by a prevalence of bizarre, multinucleated giant cells.

MalaCards based summary: Giant Cell Glioblastoma, also known as monstrocellular sarcoma, is related to glioma susceptibility 1 and sarcoma, and has symptoms including headache and seizures. An important gene associated with Giant Cell Glioblastoma is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Temozolomide and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and endothelial, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Wikipedia: 75 The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of... more...

Related Diseases for Giant Cell Glioblastoma

Diseases related to Giant Cell Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 31.6 TP53 LZTR1 IDH1 H3-3A
2 sarcoma 31.1 TP53 PIK3CA HRAS FGFR1 BRAF
3 glioblastoma 30.9 TP53 PTEN POLE PIK3R1 PIK3CA MYCN
4 pleomorphic xanthoastrocytoma 30.9 TP53 MGMT IDH1 H3-3A BRAF
5 neurofibromatosis, type i 30.7 TP53 PTEN MSH2 IDH1 HRAS EGFR
6 neurofibromatosis 30.6 TP53 PTEN MSH2 LZTR1 HRAS EGFR
7 diffuse astrocytoma 30.6 TP53 PTEN MGMT IDH1 H3-3A EGFR
8 glioma 30.6 TP53 PTEN PIK3CA MGMT IDH1 EGFR
9 anaplastic astrocytoma 30.6 TP53 PTEN MGMT IDH1 H3-3A EGFR
10 hydrocephalus 30.5 TP53 PTEN FGFR3 FGFR1
11 anaplastic pleomorphic xanthoastrocytoma 30.5 MGMT IDH1 H3-3A
12 papilloma 30.5 TP53 PTEN FGFR3 EGFR
13 high grade glioma 30.5 TP53 PTEN PIK3CA MGMT EGFR ATM
14 gemistocytic astrocytoma 30.5 TP53 PTEN MGMT IDH1
15 ganglioglioma 30.4 TP53 MYCN H3-3A BRAF
16 atypical teratoid rhabdoid tumor 30.4 TP53 MYCN IDH1 H3-3A EGFR
17 central nervous system cancer 30.4 TP53 MGMT IDH1 EGFR
18 malignant astrocytoma 30.4 TP53 PTEN MGMT IDH1 EGFR
19 idh-wildtype glioblastoma 30.3 TP53 PTEN MGMT IDH1 H3-3A EGFR
20 brain cancer 30.3 TP53 PTEN PIK3R1 PIK3CA MYCN MSH2
21 meningioma, familial 30.1 TP53 PTEN PIK3R1 PIK3CA MGMT LZTR1
22 medulloblastoma 29.9 TP53 PTEN PIK3CA MYCN MSH2 MGMT
23 gliosarcoma 29.6 TP53 TACC3 TACC1 SEPTIN14 PTEN POLE
24 rosette-forming glioneuronal tumor 10.5 PIK3CA FGFR1
25 high-grade astrocytoma 10.5 TP53 PTEN
26 plagiocephaly 10.5 FGFR3 FGFR1
27 simple partial epilepsy 10.5 PIK3CA IDH1 FGFR1
28 adult oligodendroglioma 10.4 IDH1 H3-3A FGFR1
29 cellular ependymoma 10.4 MSH2 MGMT EGFR
30 esophagus verrucous carcinoma 10.4 TP53 PIK3CA EGFR
31 verrucous carcinoma 10.4 TP53 PIK3CA EGFR
32 histoplasmosis meningitis 10.4 MGMT IDH1
33 neurofibrosarcoma 10.4 TP53 TACC1 FGFR1
34 adult brain stem glioma 10.4 MGMT IDH1 H3-3A
35 glottis squamous cell carcinoma 10.4 PTEN EGFR
36 urethra transitional cell carcinoma 10.4 TP53 EGFR BRAF
37 brain glioblastoma multiforme 10.4 TP53 MGMT EGFR
38 idh-wildtype anaplastic astrocytoma 10.4 MGMT IDH1 H3-3A
39 apocrine adenocarcinoma 10.4 TP53 PIK3CA EGFR
40 papillary adenofibroma 10.4 PTEN POLE MSH2
41 juvenile pilocytic astrocytoma 10.4 TP53 IDH1 H3-3A
42 chondroblastic osteosarcoma 10.4 TP53 IDH1 H3-3A
43 pancreatic signet ring cell adenocarcinoma 10.4 TP53 MSH2 HRAS
44 signet ring cell adenocarcinoma 10.4 TP53 MSH2 HRAS
45 astrocytoma, idh-mutant, grade 4 10.4 MGMT IDH1 H3-3A
46 fibrillary astrocytoma 10.4 TP53 IDH1 H3-3A
47 neuroma 10.4 MSH2 MGMT LZTR1 FGFR1
48 small intestine adenocarcinoma 10.4 TP53 MSH2 HRAS
49 spinal cancer 10.4 LZTR1 IDH1 H3-3A
50 anal squamous cell carcinoma 10.4 TP53 PIK3CA EGFR

Graphical network of the top 20 diseases related to Giant Cell Glioblastoma:



Diseases related to Giant Cell Glioblastoma

Symptoms & Phenotypes for Giant Cell Glioblastoma

UMLS symptoms related to Giant Cell Glioblastoma:


headache; seizures

GenomeRNAi Phenotypes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

25 (show all 40)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.61 BRAF EGFR HRAS PIK3CA
2 Decreased viability GR00055-A-2 10.61 BRAF EGFR HRAS PIK3CA
3 Decreased viability GR00221-A-1 10.61 EGFR HRAS PIK3CA FGFR1 FGFR3 PIK3R1
4 Decreased viability GR00221-A-2 10.61 HRAS PIK3CA FGFR1 FGFR3
5 Decreased viability GR00221-A-3 10.61 HRAS FGFR3 PIK3R1
6 Decreased viability GR00221-A-4 10.61 BRAF EGFR PIK3CA
7 Decreased viability GR00249-S 10.61 BRAF FGFR3
8 Decreased viability GR00301-A 10.61 BRAF
9 Decreased viability GR00381-A-1 10.61 BRAF
10 Decreased viability GR00386-A-1 10.61 FGFR1
11 Decreased viability GR00402-S-2 10.61 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.35 FGFR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.35 PIK3R1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.35 MSH2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.35 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.35 FGFR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.35 MSH2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.35 MSH2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.35 FGFR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.35 MSH2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.35 PIK3R1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.35 FGFR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.35 HRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.35 PIK3R1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.35 EGFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.35 EGFR MSH2 PIK3R1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.35 FGFR1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.35 HRAS
29 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.35 PIK3R1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.35 EGFR FGFR1 PIK3R1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.35 FGFR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.35 FGFR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.35 MSH2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.35 FGFR1 HRAS
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.35 EGFR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.35 HRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.35 EGFR
38 no effect GR00402-S-1 10.19 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
39 no effect GR00402-S-2 10.19 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
40 Reduced mammosphere formation GR00396-S 9.5 ATM BRAF EGFR HRAS PIK3R1 POLE

MGI Mouse Phenotypes related to Giant Cell Glioblastoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.43 ATM BRAF EGFR FGFR1 FGFR3 HRAS
2 neoplasm MP:0002006 10.42 ATM BRAF EGFR FGFR3 HRAS MGMT
3 homeostasis/metabolism MP:0005376 10.41 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
4 growth/size/body region MP:0005378 10.4 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
5 normal MP:0002873 10.34 BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
6 cellular MP:0005384 10.28 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
7 muscle MP:0005369 10.27 BRAF EGFR FGFR1 HRAS LZTR1 MYCN
8 endocrine/exocrine gland MP:0005379 10.25 ATM BRAF EGFR FGFR1 HRAS MGMT
9 renal/urinary system MP:0005367 10.23 BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
10 no phenotypic analysis MP:0003012 10.19 EGFR FGFR1 FGFR3 HRAS MGMT MYCN
11 embryo MP:0005380 10.19 ATM BRAF EGFR FGFR1 H3-3A MYCN
12 digestive/alimentary MP:0005381 10.18 BRAF EGFR FGFR1 FGFR3 HRAS MSH2
13 immune system MP:0005387 10.18 ATM BRAF EGFR FGFR1 FGFR3 IDH1
14 limbs/digits/tail MP:0005371 10.16 BRAF EGFR FGFR1 FGFR3 MYCN PTEN
15 cardiovascular system MP:0005385 10.14 ATM BRAF EGFR FGFR1 HRAS LZTR1
16 craniofacial MP:0005382 10.11 BRAF EGFR FGFR1 FGFR3 HRAS LZTR1
17 adipose tissue MP:0005375 10.09 ATM BRAF EGFR PIK3CA PIK3R1 PTEN
18 skeleton MP:0005390 10.03 BRAF EGFR FGFR1 FGFR3 HRAS IDH1
19 hematopoietic system MP:0005397 10 ATM BRAF EGFR FGFR1 FGFR3 IDH1
20 respiratory system MP:0005388 9.97 BRAF EGFR FGFR3 HRAS IDH1 MGMT
21 mortality/aging MP:0010768 9.91 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
22 integument MP:0010771 9.4 ATM BRAF EGFR FGFR1 FGFR3 HRAS

Drugs & Therapeutics for Giant Cell Glioblastoma

Drugs for Giant Cell Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
2
Sargramostim Approved, Investigational Phase 3 123774-72-1
3
Molgramostim Investigational Phase 3 99283-10-0
4
Rindopepimut Investigational Phase 3 1108208-65-6
5 Alkylating Agents Phase 3
6 Antineoplastic Agents, Alkylating Phase 3
7 Immunologic Factors Phase 3
8 Antineoplastic Agents, Immunological Phase 3
9
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
10
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
11
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
12
Aflibercept Approved Phase 2 862111-32-8 124490314
13
Acetic acid Approved Phase 2 64-19-7 176
14
Plerixafor Approved Phase 1, Phase 2 110078-46-1 65015
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
17
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
18
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
20
Lapatinib Approved, Investigational Phase 1, Phase 2 231277-92-2, 388082-78-8 208908
21
Basiliximab Approved, Investigational Phase 2 179045-86-4
22
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
23
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
24
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
25
Coenzyme M Approved, Investigational Phase 1, Phase 2 3375-50-6 598 23662354
26
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3 135329020
27
Aminolevulinic acid Approved Phase 2 106-60-5 137
28
Lopinavir Approved Phase 2 192725-17-0 92727
29
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
30
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 43805 11947679 6857599
31
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8 5280382 445354
32
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 1, Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
33
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
34
Arginine Approved, Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
35
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
36
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
37
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
38
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-16-7, 110-17-8 444266 444972
39
(-)-Gossypol Investigational Phase 2 303-45-7, 90141-22-3 3503
40
Zuretinol acetate Investigational Phase 2 127-47-9, 29584-22-3 10245972
41
Trebananib Investigational Phase 2 894356-79-7
42
Tipifarnib Investigational Phase 2 192185-72-1 159324
43
Motexafin gadolinium Investigational Phase 1, Phase 2 246252-06-2
44
Misonidazole Investigational Phase 2 13551-87-6 26105
45
Imetelstat Investigational Phase 2 868169-64-6
46
Fenretinide Investigational Phase 2 65646-68-6 5288209
47 Neurotransmitter Agents Phase 1, Phase 2
48 Radiopharmaceuticals Phase 1, Phase 2
49 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
50 Antimetabolites Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
2 Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma Unknown status NCT01730950 Phase 2
3 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
4 A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs Completed NCT00662506 Phase 1, Phase 2 Cediranib Maleate;Temozolomide
5 A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme Completed NCT00445588 Phase 2 erlotinib hydrochloride;sorafenib tosylate
6 Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Completed NCT00423735 Phase 2 Dasatinib
7 A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma Completed NCT00379080 Phase 1, Phase 2 tandutinib
8 Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme Completed NCT00641706 Phase 2 vorinostat;bortezomib
9 A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
10 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Completed NCT00731731 Phase 1, Phase 2 Temozolomide;Vorinostat
11 A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme Completed NCT00540722 Phase 2 R-(-)-gossypol acetic acid
12 A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM Completed NCT01977677 Phase 1, Phase 2 temozolomide;plerixafor
13 A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
14 A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma Completed NCT00459381 Phase 2 pazopanib hydrochloride
15 A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Completed NCT01894061 Phase 2
16 Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Completed NCT00369590 Phase 2
17 A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
18 Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma) Completed NCT00014170 Phase 2 gefitinib
19 A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme Completed NCT00016328 Phase 2 temsirolimus
20 Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma Completed NCT01609790 Phase 2
21 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
22 Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
23 Phase II Study of R115777 for the Treatment of Adults With Newly Diagnosed Glioblastoma Multiforme Completed NCT00058097 Phase 2 tipifarnib
24 A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC #715055] With Radiation Therapy in Glioblastoma Multiforme Completed NCT00052208 Phase 1, Phase 2 gefitinib
25 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
26 Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma Completed NCT02366728 Phase 2 Temozolomide;Saline;Basiliximab
27 Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas Completed NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
28 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
29 A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme Completed NCT00039494 Phase 2 erlotinib hydrochloride;temozolomide
30 A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme Completed NCT00980343 Phase 2 vismodegib
31 Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
32 A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00305864 Phase 1, Phase 2 Motexafin Gadolinium;Temozolomide
33 A Phase II Study of AZD2171 in Recurrent Glioblastoma Completed NCT00305656 Phase 2 cediranib maleate
34 Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Recurrent Glioblastoma Completed NCT00238303 Phase 2 vorinostat
35 Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme Completed NCT00004146 Phase 2 carboxyamidotriazole
36 Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme Completed NCT01648348 Phase 1, Phase 2
37 A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00085254 Phase 1, Phase 2 cilengitide;temozolomide
38 A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas Completed NCT00045708 Phase 1, Phase 2 ixabepilone;Anticonvulsant
39 Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI Completed NCT00902577 Phase 2 FMISO
40 Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy) Completed NCT01753713 Phase 2 dovitinib
41 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
42 A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Completed NCT01498328 Phase 2 Bevacizumab;Rindopepimut (CDX-110) with GM-CSF;KLH
43 Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Recruiting NCT03027388 Phase 2 LB-100
44 A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma Recruiting NCT05218408 Phase 1, Phase 2
45 Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma Active, not recruiting NCT01149850 Phase 2 temozolomide
46 Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Active, not recruiting NCT02179086 Phase 2 temozolomide
47 Phase II Clinical Trial of HSV G207 With a Single 5 Gy Radiation Dose in Children With Recurrent High-Grade Glioma Not yet recruiting NCT04482933 Phase 2 Biological G207
48 A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma Terminated NCT01836549 Phase 2 imetelstat sodium
49 Phase II Trial of Ritonavir/Lopinavir in Patients With Progressive of Recurrent High-Grade Gliomas Terminated NCT01095094 Phase 2 ritonavir;lopinavir
50 A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma Terminated NCT01122901 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097

Search NIH Clinical Center for Giant Cell Glioblastoma

Genetic Tests for Giant Cell Glioblastoma

Anatomical Context for Giant Cell Glioblastoma

Organs/tissues related to Giant Cell Glioblastoma:

MalaCards : Brain, Eye, Endothelial, Liver, Medulla Oblongata, Cerebellum, Cortex

Publications for Giant Cell Glioblastoma

Articles related to Giant Cell Glioblastoma:

(show top 50) (show all 142)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Genetic profile of the giant cell glioblastoma. 53 62
10068201 1999
3
p53 mutations versus EGF receptor expression in giant cell glioblastomas. 53 62
9370234 1997
4
Gliosarcoma with unusual glial components: Two case reports. 62
35644835 2022
5
Morphogenetic and Imaging Characteristics in Giant Cell Glioblastoma. 62
36005160 2022
6
Glioblastoma: Changing concepts in the WHO CNS5 classification. 62
35562131 2022
7
Case report: Awake craniotomy during pregnancy for resection of glioblastoma. 62
35367747 2022
8
IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. 62
34952640 2021
9
SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. 62
34103668 2021
10
Cyclin D1 expression in ganglioglioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma. 62
34022185 2021
11
Differentiating Giant Cell Glioblastoma from Classic Glioblastoma With Diffusion-Weighted Imaging. 62
33127573 2021
12
Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review. 62
34094927 2021
13
Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database. 62
34899553 2021
14
Pediatric Giant Cell Glioblastoma Presenting with Intracranial Dissemination at Diagnosis: A Case Report. 62
35079457 2021
15
Giant cell glioblastoma multiforme presents as acute pathological nontraumatic subdural haematoma. 62
33369511 2020
16
Giant cell glioblastoma in 6-year-old kid: Report of an unusual case. 62
33363854 2020
17
Characterization and Histological Examination of a Rare Giant Cell Glioblastoma. 62
32821583 2020
18
Update on Circumscribed Gliomas and Glioneuronal Tumors. 62
32389265 2020
19
Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma. 62
33392505 2020
20
TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. 62
32642724 2020
21
Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damage. 62
31655917 2020
22
Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. 62
30861589 2019
23
Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study. 62
31464386 2019
24
Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma. 62
31009783 2019
25
Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma. 62
30368636 2019
26
Subgaleal and brain abscesses due to Salmonella enteritidis following craniotomy for giant cell glioblastoma multiforme: A case report and literature review. 62
31528375 2019
27
An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female. 62
31394931 2019
28
Imaging findings in the progression of a giant cell glioblastoma. 62
30128062 2018
29
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 62
30783357 2018
30
Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. 62
30279958 2018
31
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 62
30443141 2018
32
Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature. 62
29805603 2018
33
Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database. 62
28288541 2017
34
IDH-mutant giant cell glioblastoma: A neglected tumor variant? 62
29035191 2017
35
Giant Cell Glioblastoma in a Child with Clinical and Family History of Neurofibromatosis. 62
29114311 2017
36
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. 62
28261869 2017
37
Radiologic Dilemma in an Extra-Axial Petroclival Lesion: Low Grade versus High Grade. 62
28109858 2017
38
Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. 62
28161760 2017
39
Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. 62
26443480 2016
40
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. 62
27013816 2016
41
MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. 62
27253461 2016
42
Pediatric Giant Cell Glioblastoma Mimicking Hemorrhage Secondary to Ischemic Stroke. 62
26344331 2015
43
Giant cell glioblastoma with calcification and long-term survival. 62
26960525 2015
44
A spontaneously occurring malignant pituicytoma in a male sprague dawley rat. 62
26441479 2015
45
Adult classical glioblastoma with a BRAF V600E mutation. 62
25885250 2015
46
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients. 62
25037316 2014
47
Treatment and survival of patients harboring histological variants of glioblastoma. 62
24980627 2014
48
[Gliosarcoma of cerebral hemispheres: a clinicopathologic study of 10 cases]. 62
25567590 2014
49
Estimating the surface area of nonconvex particles from central planar sections. 62
24832486 2014
50
Cerebellar giant cell glioblastoma multiforme in an adult. 62
25002780 2014

Variations for Giant Cell Glioblastoma

ClinVar genetic disease variations for Giant Cell Glioblastoma:

5 (show top 50) (show all 233)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 H3-3A NM_002107.7(H3-3A):c.103G>A (p.Gly35Arg) SNV Other
438766 rs1553260624 GRCh37: 1:226252155-226252155
GRCh38: 1:226064454-226064454
2 MED12 NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp) SNV Other
438772 rs1556339256 GRCh37: X:70357729-70357729
GRCh38: X:71137879-71137879
3 BCOR NM_001123385.2(BCOR):c.3883_3884del (p.Leu1296fs) MICROSAT Other
284290 rs886042842 GRCh37: X:39922288-39922289
GRCh38: X:40063035-40063036
4 MSH2 NM_000251.3(MSH2):c.1958_1965del (p.Asn653fs) DEL Pathogenic
590849 rs1558518449 GRCh37: 2:47702360-47702367
GRCh38: 2:47475221-47475228
5 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Likely Pathogenic
73058 rs121913254 GRCh37: 1:115256530-115256530
GRCh38: 1:114713909-114713909
6 TP53 NM_000546.6(TP53):c.641A>T (p.His214Leu) SNV Likely Pathogenic
376616 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
7 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely Pathogenic
376478 rs1057519929 GRCh37: 3:178916854-178916854
GRCh38: 3:179199066-179199066
8 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely Pathogenic
12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
9 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely Pathogenic
13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
10 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely Pathogenic
12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
11 IDH1 NM_005896.4(IDH1):c.395G>A (p.Arg132His) SNV Likely Pathogenic
156444 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388
12 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely Pathogenic
127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
13 TP53 NM_000546.6(TP53):c.584T>A (p.Ile195Asn) SNV Likely Pathogenic
376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
14 TP53 NM_000546.6(TP53):c.374C>T (p.Thr125Met) SNV Likely Pathogenic
183748 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
15 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely Pathogenic
177791 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
16 TP53 NM_000546.6(TP53):c.730G>T (p.Gly244Cys) SNV Likely Pathogenic
376599 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
17 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
18 TP53 NM_000546.6(TP53):c.796G>C (p.Gly266Arg) SNV Likely Pathogenic
376605 rs1057519990 GRCh37: 17:7577142-7577142
GRCh38: 17:7673824-7673824
19 TP53 NM_000546.6(TP53):c.712T>C (p.Cys238Arg) SNV Likely Pathogenic
376576 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
20 TP53 NM_000546.6(TP53):c.374C>G (p.Thr125Arg) SNV Likely Pathogenic
376667 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
21 TP53 NM_000546.6(TP53):c.535C>T (p.His179Tyr) SNV Likely Pathogenic
127815 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
22 TP53 NM_000546.6(TP53):c.580C>T (p.Leu194Phe) SNV Likely Pathogenic
127817 rs587780071 GRCh37: 17:7578269-7578269
GRCh38: 17:7674951-7674951
23 TP53 NM_000546.6(TP53):c.658T>C (p.Tyr220His) SNV Likely Pathogenic
376687 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
24 TP53 NM_000546.6(TP53):c.637C>G (p.Arg213Gly) SNV Likely Pathogenic
376651 rs397516436 GRCh37: 17:7578212-7578212
GRCh38: 17:7674894-7674894
25 TP53 NM_000546.6(TP53):c.817C>A (p.Arg273Ser) SNV Likely Pathogenic
376656 rs121913343 GRCh37: 17:7577121-7577121
GRCh38: 17:7673803-7673803
26 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely Pathogenic
12365 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
27 TP53 NM_000546.6(TP53):c.701A>G (p.Tyr234Cys) SNV Likely Pathogenic
127820 rs587780073 GRCh37: 17:7577580-7577580
GRCh38: 17:7674262-7674262
28 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Likely Pathogenic
135359 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
29 TP53 NM_000546.6(TP53):c.824G>C (p.Cys275Ser) SNV Likely Pathogenic
376583 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
30 TP53 NM_000546.6(TP53):c.536A>G (p.His179Arg) SNV Likely Pathogenic
376606 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
31 TP53 NM_000546.6(TP53):c.731G>A (p.Gly244Asp) SNV Likely Pathogenic
372785 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
32 TP53 NM_000546.6(TP53):c.845G>A (p.Arg282Gln) SNV Likely Pathogenic
237956 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
33 TP53 NM_000546.6(TP53):c.536A>T (p.His179Leu) SNV Likely Pathogenic
376608 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
34 TP53 NM_000546.6(TP53):c.746G>C (p.Arg249Thr) SNV Likely Pathogenic
376015 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
35 TP53 NM_000546.6(TP53):c.797G>T (p.Gly266Val) SNV Likely Pathogenic
233303 rs193920774 GRCh37: 17:7577141-7577141
GRCh38: 17:7673823-7673823
36 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Likely Pathogenic
12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
37 TP53 NM_000546.6(TP53):c.842A>T (p.Asp281Val) SNV Likely Pathogenic
182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
38 TP53 NM_000546.6(TP53):c.713G>C (p.Cys238Ser) SNV Likely Pathogenic
376575 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
39 TP53 NM_000546.6(TP53):c.613T>C (p.Tyr205His) SNV Likely Pathogenic
376685 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
40 TP53 NM_000546.6(TP53):c.658T>A (p.Tyr220Asn) SNV Likely Pathogenic
376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
41 TP53 NM_000546.6(TP53):c.725G>T (p.Cys242Phe) SNV Likely Pathogenic
376578 rs121912655 GRCh37: 17:7577556-7577556
GRCh38: 17:7674238-7674238
42 TP53 NM_000546.6(TP53):c.844C>G (p.Arg282Gly) SNV Likely Pathogenic
140821 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
43 TP53 NM_000546.6(TP53):c.583A>T (p.Ile195Phe) SNV Likely Pathogenic
376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
44 TP53 NM_000546.6(TP53):c.764T>A (p.Ile255Asn) SNV Likely Pathogenic
232289 rs876659675 GRCh37: 17:7577517-7577517
GRCh38: 17:7674199-7674199
45 TP53 NM_000546.6(TP53):c.733G>T (p.Gly245Cys) SNV Likely Pathogenic
12349 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
46 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Likely Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
47 PTEN NM_000314.8(PTEN):c.698G>A (p.Arg233Gln) SNV Likely Pathogenic
376510 rs770025422 GRCh37: 10:89717673-89717673
GRCh38: 10:87957916-87957916
48 TP53 NM_000546.6(TP53):c.734G>C (p.Gly245Ala) SNV Likely Pathogenic
265357 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
49 TP53 NM_000546.6(TP53):c.734G>T (p.Gly245Val) SNV Likely Pathogenic
376603 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
50 TP53 NM_000546.6(TP53):c.646G>T (p.Val216Leu) SNV Likely Pathogenic
376670 rs730882025 GRCh37: 17:7578203-7578203
GRCh38: 17:7674885-7674885

Expression for Giant Cell Glioblastoma

Search GEO for disease gene expression data for Giant Cell Glioblastoma.

Pathways for Giant Cell Glioblastoma

Pathways related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 136)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 ATM BRAF EGFR FGFR1 FGFR3 H3-3A
2
Show member pathways
13.91 TP53 PTEN PIK3R1 HRAS H3-3A FGFR3
3 13.84 BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
4
Show member pathways
13.81 TP53 PTEN PIK3R1 PIK3CA MSH2 IDH1
5
Show member pathways
13.63 TP53 PIK3R1 PIK3CA HRAS H3-3A FGFR3
6
Show member pathways
13.49 TP53 PTEN PIK3R1 HRAS FGFR3 FGFR1
7
Show member pathways
13.47 PTEN PIK3R1 PIK3CA HRAS FGFR3 FGFR1
8
Show member pathways
13.42 TP53 PTEN PIK3R1 PIK3CA MGMT HRAS
9
Show member pathways
13.16 EGFR FGFR1 FGFR3 PIK3CA PIK3R1 PTEN
10
Show member pathways
13.16 BRAF EGFR FGFR1 FGFR3 HRAS PIK3R1
11
Show member pathways
13.03 TP53 PTEN PIK3R1 PIK3CA HRAS FGFR3
12
Show member pathways
13.02 EGFR HRAS PIK3CA PIK3R1 PTEN TP53
13
Show member pathways
12.94 PTEN PIK3R1 PIK3CA HRAS BRAF
14
Show member pathways
12.93 TP53 PIK3R1 PIK3CA HRAS BRAF
15
Show member pathways
12.93 PIK3R1 PIK3CA HRAS EGFR BRAF
16
Show member pathways
12.93 PTEN PIK3R1 PIK3CA HRAS FGFR3 FGFR1
17 12.88 BRAF EGFR FGFR1 FGFR3 HRAS MYCN
18
Show member pathways
12.84 PTEN PIK3R1 PIK3CA HRAS EGFR
19
Show member pathways
12.8 PIK3R1 PIK3CA HRAS FGFR3 FGFR1
20
Show member pathways
12.79 PTEN PIK3R1 PIK3CA FGFR3 FGFR1 EGFR
21
Show member pathways
12.76 TP53 PIK3R1 HRAS EGFR BRAF
22 12.74 TP53 PTEN PIK3CA HRAS FGFR3 FGFR1
23
Show member pathways
12.71 TP53 POLE MSH2 MGMT ATM
24
Show member pathways
12.71 ATM EGFR FGFR1 FGFR3 HRAS PIK3CA
25
Show member pathways
12.7 EGFR HRAS MSH2 PIK3CA PIK3R1 TP53
26
Show member pathways
12.69 PIK3R1 PIK3CA HRAS FGFR3 FGFR1 BRAF
27 12.62 TP53 TACC3 MSH2 MGMT ATM
28
Show member pathways
12.59 TP53 PIK3R1 PIK3CA HRAS EGFR BRAF
29
Show member pathways
12.57 TP53 PTEN PIK3R1 PIK3CA HRAS BRAF
30
Show member pathways
12.52 PIK3R1 PIK3CA HRAS FGFR3 FGFR1
31
Show member pathways
12.51 PIK3R1 HRAS FGFR3 FGFR1 EGFR
32 12.5 BRAF EGFR FGFR1 FGFR3 HRAS TP53
33
Show member pathways
12.49 PIK3R1 PIK3CA HRAS EGFR
34
Show member pathways
12.49 PIK3R1 PIK3CA HRAS BRAF
35
Show member pathways
12.49 PIK3R1 PIK3CA HRAS FGFR3 FGFR1 EGFR
36
Show member pathways
12.47 TP53 PTEN PIK3R1 PIK3CA MSH2 HRAS
37
Show member pathways
12.45 TP53 PIK3R1 PIK3CA HRAS FGFR3 FGFR1
38
Show member pathways
12.43 PTEN PIK3R1 PIK3CA HRAS
39
Show member pathways
12.42 PIK3R1 PIK3CA HRAS EGFR
40
Show member pathways
12.42 TP53 PIK3R1 PIK3CA HRAS FGFR1
41
Show member pathways
12.41 PTEN PIK3R1 PIK3CA HRAS
42
Show member pathways
12.38 BRAF EGFR PIK3CA PIK3R1 PTEN
43 12.38 PTEN PIK3R1 PIK3CA HRAS EGFR BRAF
44
Show member pathways
12.37 TP53 PTEN PIK3R1 PIK3CA HRAS
45
Show member pathways
12.36 BRAF FGFR1 FGFR3 HRAS PIK3CA PIK3R1
46
Show member pathways
12.35 PIK3R1 PIK3CA HRAS EGFR
47
Show member pathways
12.34 PIK3R1 PIK3CA HRAS EGFR
48
Show member pathways
12.33 PTEN HRAS FGFR3 FGFR1 EGFR
49 12.32 EGFR FGFR1 FGFR3 HRAS PIK3CA PIK3R1
50 12.31 TP53 PIK3R1 MSH2 EGFR BRAF

GO Terms for Giant Cell Glioblastoma

Biological processes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.13 PTEN HRAS FGFR3 EGFR BRAF
2 negative regulation of neuron apoptotic process GO:0043524 10.1 PIK3CA MSH2 HRAS BRAF
3 regulation of cell cycle GO:0051726 10.06 TP53 PTEN MSH2 HRAS ATM
4 epidermal growth factor receptor signaling pathway GO:0007173 9.99 PIK3CA EGFR BRAF
5 phosphatidylinositol 3-kinase signaling GO:0014065 9.95 PIK3CA PIK3R1 PTEN
6 cell population proliferation GO:0008283 9.91 TP53 TACC3 TACC1 PTEN EGFR
7 cellular response to gamma radiation GO:0071480 9.88 ATM HRAS TP53
8 MAPK cascade GO:0000165 9.85 HRAS FGFR3 FGFR1 EGFR BRAF
9 determination of adult lifespan GO:0008340 9.73 TP53 MSH2 ATM
10 phosphorylation GO:0016310 9.56 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR BRAF
11 regulation of axon regeneration GO:0048679 9.52 PTEN BRAF
12 cellular response to endogenous stimulus GO:0071495 9.32 FGFR3 FGFR1
13 positive regulation of miRNA maturation GO:1903800 8.92 TP53 MYCN EGFR

Molecular functions related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.86 POLE PIK3CA MGMT FGFR3 FGFR1 EGFR
2 protein tyrosine kinase activity GO:0004713 9.7 BRAF EGFR FGFR1 FGFR3
3 fibroblast growth factor receptor activity GO:0005007 9.62 FGFR3 FGFR1
4 kinase activity GO:0016301 9.56 PIK3R1 PIK3CA FGFR3 FGFR1 EGFR BRAF
5 protein serine/threonine kinase activator activity GO:0043539 9.54 PIK3R1 PIK3CA HRAS
6 nucleotide binding GO:0000166 9.36 SEPTIN14 POLE PIK3CA MSH2 HRAS FGFR3

Sources for Giant Cell Glioblastoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....